logo
#

Latest news with #Tanigaki

PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR
PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR

Malaysian Reserve

time22-05-2025

  • Health
  • Malaysian Reserve

PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR

PROVISION Study, Prospective Randomized Trial Evaluating Clinical Outcomes of FFRangio Versus FFR Guidance, Demonstrates Similar MACE Rates at One Year PARIS, May 22, 2025 /PRNewswire/ — Today at the annual EuroPCR conference taking place in Paris, France, Dr. Toru Tanigaki of Gifu Heart Center in Gifu, Japan presented the one-year results of the physician-initiated PROVISION1 Study. At TCT 2024, investigators shared that the PROVISION Study met its non-inferiority primary endpoint and revealed economic and resource utilization advantages for the FFRangio technology over traditional invasive FFR. The PROVISION Study is the first Japanese prospective randomized controlled trial (RCT) comparing the outcomes of an angio-based technology compared to invasive wire-based physiology and enrolled 401 patients across 13 centers in Japan. Patients with intermediate coronary lesions (30-90% diameter stenosis) were randomized 1:1 to either the wire-based FFR arm, in which the treatment decision was determined based on FFR values obtained using an invasive pressure wire, or the FFRangio arm, in which the treatment decision was based on FFRangio values. Based on the functional evaluations, either revascularization (PCI) and optimal medical management (OMT) or OMT alone were selected, and patients were followed clinically for at least one year. During a Hotline / Late-Breaking Trials session at EuroPCR 2025, Dr. Tanigaki presented the rates of major adverse cardiac events (MACE) at one year for patients treated according to FFRangio guidance versus FFR guidance. MACE was defined as a composite of death from any cause, nonfatal myocardial infarction (MI) or unplanned revascularization. MACE at one year was 9.9% for the FFRangio arm versus 12.6% for the FFR arm [HR 0.80 (0.42 to 1.51), p = 0.489]. MACE excluding periprocedural MI was 3.5% for the FFRangio arm versus 6.0% for the FFR arm [HR 0.58 (0.13 to 1.42), p = 0.167]. The rates of all-cause death, myocardial infarction and target vessel revascularization at one year were all similar in the FFRangio arm and FFR arm. 'The CathWorks FFRangio® System has already demonstrated the highest diagnostic accuracy compared to wire-based FFR among non-hyperemic indices and angio-based technologies. The FFRangio System not only eliminates the drawbacks of invasive wire-based technologies that have limited the overall adoption of physiology but also provides tools that optimize clinical decision making. With the addition of this new body of clinical evidence demonstrating patients treated according to FFRangio guidance have similar outcomes to those treated based on invasive FFR guidance while potentially reducing procedural resources and costs, we are truly embarking on a new era in physiology, transforming FFRangio into the new standard of care,' said Ramin Mousavi, CathWorks President & CEO. ABOUT CATHWORKS CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit and follow @CathWorks on LinkedIn. 1. Prospective Randomized trial of clinical Outcomes of angiography-based fractional flow reserve guidance Versus wIre-baSed fractIOnal flow reserve guidance (PROVISION) study is an investigation of the Utility of Coronary Angiography (FFRangio) in Comparison to Coronary Fractional Flow Reserve (FFR) in the Determination of Treatment Planning and the Clinical Prognosis in Patients with Chronic Phase Coronary Artery Disease Investors:Mike Media:Sarita Photo – – View original content:

PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR
PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR

Cision Canada

time22-05-2025

  • Health
  • Cision Canada

PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR

PARIS, May 22, 2025 /CNW/ -- Today at the annual EuroPCR conference taking place in Paris, France, Dr. Toru Tanigaki of Gifu Heart Center in Gifu, Japan presented the one-year results of the physician-initiated PROVISION 1 Study. At TCT 2024, investigators shared that the PROVISION Study met its non-inferiority primary endpoint and revealed economic and resource utilization advantages for the FFRangio technology over traditional invasive FFR. The PROVISION Study is the first Japanese prospective randomized controlled trial (RCT) comparing the outcomes of an angio-based technology compared to invasive wire-based physiology and enrolled 401 patients across 13 centers in Japan. Patients with intermediate coronary lesions (30-90% diameter stenosis) were randomized 1:1 to either the wire-based FFR arm, in which the treatment decision was determined based on FFR values obtained using an invasive pressure wire, or the FFRangio arm, in which the treatment decision was based on FFRangio values. Based on the functional evaluations, either revascularization (PCI) and optimal medical management (OMT) or OMT alone were selected, and patients were followed clinically for at least one year. During a Hotline / Late-Breaking Trials session at EuroPCR 2025, Dr. Tanigaki presented the rates of major adverse cardiac events (MACE) at one year for patients treated according to FFRangio guidance versus FFR guidance. MACE was defined as a composite of death from any cause, nonfatal myocardial infarction (MI) or unplanned revascularization. MACE at one year was 9.9% for the FFRangio arm versus 12.6% for the FFR arm [HR 0.80 (0.42 to 1.51), p = 0.489]. MACE excluding periprocedural MI was 3.5% for the FFRangio arm versus 6.0% for the FFR arm [HR 0.58 (0.13 to 1.42), p = 0.167]. The rates of all-cause death, myocardial infarction and target vessel revascularization at one year were all similar in the FFRangio arm and FFR arm. "The CathWorks FFRangio ® System has already demonstrated the highest diagnostic accuracy compared to wire-based FFR among non-hyperemic indices and angio-based technologies. The FFRangio System not only eliminates the drawbacks of invasive wire-based technologies that have limited the overall adoption of physiology but also provides tools that optimize clinical decision making. With the addition of this new body of clinical evidence demonstrating patients treated according to FFRangio guidance have similar outcomes to those treated based on invasive FFR guidance while potentially reducing procedural resources and costs, we are truly embarking on a new era in physiology, transforming FFRangio into the new standard of care," said Ramin Mousavi, CathWorks President & CEO. ABOUT CATHWORKS CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio ® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit and follow @CathWorks on LinkedIn. Investors: Mike Feher [email protected] Media: Sarita Monico [email protected]

Japanese action choreographer wins prize at Hong Kong Film Awards
Japanese action choreographer wins prize at Hong Kong Film Awards

Kyodo News

time29-04-2025

  • Entertainment
  • Kyodo News

Japanese action choreographer wins prize at Hong Kong Film Awards

KYODO NEWS - 15 hours ago - 17:58 | Arts, World, All, Japan Japan's Kenji Tanigaki has won the best action choreography prize for his work on the Hong Kong film "Twilight of the Warriors: Walled In" at the Hong Kong Film Awards. Inspired by action star Jackie Chan, Tanigaki built his career as a stuntman in Hong Kong and served as action director of Donnie Yen's "Sakra" and Japanese film "Rurouni Kenshin." Receiving a commemorative gift from Japanese action actor Yasuaki Kurata, who has appeared in many Hong Kong movies, at the award ceremony Sunday, Tanigaki said, "When I apprenticed under Mr. Kurata in 1989, my dream was to be recognized as a Hong Kong film person. Today, I can finally say I've become one." Twilight of the Warriors, directed by Soi Cheang and starring Raymond Lam, won awards in several categories including best director and best actor. The film was released in Hong Kong last year. It is set in the Kowloon Walled City in the 1980s during the British colonial era. It blends martial arts with nostalgia for the demolished city, following a male illegal immigrant from mainland China who joins friends to battle rival factions. Related coverage: Japanese anime wins 2nd prize at Berlin film festival Japan Oscar-nominated film to be reedited amid legal concerns Japanese long-form documentary film up for Academy Award for 1st time

Japanese action choreographer wins prize at Hong Kong Film Awards
Japanese action choreographer wins prize at Hong Kong Film Awards

The Mainichi

time28-04-2025

  • Entertainment
  • The Mainichi

Japanese action choreographer wins prize at Hong Kong Film Awards

HONG KONG (Kyodo) -- Japan's Kenji Tanigaki has won the best action choreography prize for his work on the Hong Kong film "Twilight of the Warriors: Walled In" at the Hong Kong Film Awards. Inspired by action star Jackie Chan, Tanigaki built his career as a stuntman in Hong Kong and served as action director of Donnie Yen's "Sakra" and Japanese film "Rurouni Kenshin." Receiving a commemorative gift from Japanese action actor Yasuaki Kurata, who has appeared in many Hong Kong movies, at the award ceremony Sunday, Tanigaki said, "When I apprenticed under Mr. Kurata in 1989, my dream was to be recognized as a Hong Kong film person. Today, I can finally say I've become one." Twilight of the Warriors, directed by Soi Cheang and starring Raymond Lam, won awards in several categories including best director and best actor. The film was released in Hong Kong last year. It is set in the Kowloon Walled City in the 1980s during the British colonial era. It blends martial arts with nostalgia for the demolished city, following a male illegal immigrant from mainland China who joins friends to battle rival factions.

Japanese action choreographer wins prize at Hong Kong Film Awards
Japanese action choreographer wins prize at Hong Kong Film Awards

Kyodo News

time28-04-2025

  • Entertainment
  • Kyodo News

Japanese action choreographer wins prize at Hong Kong Film Awards

KYODO NEWS - 30 minutes ago - 17:58 | Arts, World, All, Japan Japan's Kenji Tanigaki has won the best action choreography prize for his work on the Hong Kong film "Twilight of the Warriors: Walled In" at the Hong Kong Film Awards. Inspired by action star Jackie Chan, Tanigaki built his career as a stuntman in Hong Kong and served as action director of Donnie Yen's "Sakra" and Japanese film "Rurouni Kenshin." Receiving a commemorative gift from Japanese action actor Yasuaki Kurata, who has appeared in many Hong Kong movies, at the award ceremony Sunday, Tanigaki said, "When I apprenticed under Mr. Kurata in 1989, my dream was to be recognized as a Hong Kong film person. Today, I can finally say I've become one." Twilight of the Warriors, directed by Soi Cheang and starring Raymond Lam, won awards in several categories including best director and best actor. The film was released in Hong Kong last year. It is set in the Kowloon Walled City in the 1980s during the British colonial era. It blends martial arts with nostalgia for the demolished city, following a male illegal immigrant from mainland China who joins friends to battle rival factions. Related coverage: Japanese anime wins 2nd prize at Berlin film festival Japan Oscar-nominated film to be reedited amid legal concerns Japanese long-form documentary film up for Academy Award for 1st time

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store